Jean-Jacques Kiladjian/LinkedIn
Nov 24, 2025, 10:25
Jean Jacques Kiladjian Visits INSERM-supervised CIC 1408 Investigation Center
Jean Jacques Kiladjian, Head of Clinical Research Department of Inserm, shared on LinkedIn:
”A busy day visiting the INSERM-supervised CIC 1408 clinical investigation center in Saint-Etienne during its evaluation by HCERES, showcasing its dynamism and impressive scientific output in clinical pharmacology and public health, with a strong focus on vascular/hemostasis, immunomonitoring, inflammatory diseases (IBD and systemic), vaccinology, population health, paramedical research, and mental health.”
Stay updated with Hemostasis Today.
-
Aug 6, 2026, 18:11Filipe Gonçalves: Are DOACs Truly Pharmacokinetically Predictable or Simply Pharmacodynamically Forgiving?
-
Aug 6, 2026, 18:04Wolfgang Miesbach: Base Editing Expands Therapeutic Targets for Hemophilia B
-
Aug 6, 2026, 18:03Identifing Gaps in How IDA is Recognised and Managed in Children – ISBT
-
Aug 6, 2026, 18:03Expanding Access to Care for People With Hemophilia in Côte d’Ivoire – WFH
-
Aug 6, 2026, 18:00Kavita Vinod Paul: Transforming Lives Through Comprehensive Care and Community Leadership
-
Aug 6, 2026, 17:59BSH Good Practice Paper on Multidisciplinary Hematology and Gynecology Care – British Journal of Haematology
-
Aug 6, 2026, 17:38Cameron Cook: How Cost-Effective Is Evolocumab for Patients at High Cardiovascular Risk?
-
Aug 6, 2026, 15:53Pall T. Onundarson: Frail Elderly Korean Atrial Fibrillation Patients Do Worse If Switched to DOACs in a Nationwide Observational Study
-
Aug 6, 2026, 15:46Zain Khalpey: Left Atrial Appendage Closure vs Oral Anticoagulation in Atrial Fibrillation